Bio-Techne Corp (TECH) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

Total Revenue Chart for Bio-Techne Corp

Bio-Techne Corp (TECH) revenue for FY2026 was USD 1.2B, a -0.4% change from FY2025. Bio-Techne Corp's revenue grew from USD 12.5M in 1989 to USD 1.2B in 2026 (9620.3% over 37 years). Earnings per share grew from USD 0.16 in 2000 to USD 1.76 in 2023 (1019.3%). Revenue compound annual growth rate: 5-year CAGR of 5.5%, 10-year CAGR of 9.3%, 20-year CAGR of 9.4%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$11.28B
Implied Share Price
$72.40
Enterprise Value
$11.31B
Revenue (TTM)
$1.22B
EBITDA
$355.05M
Profit Margin
14.97%
Trailing P/E
62.41
Forward P/E
34.60
Price/Book (MRQ)
5.35
Price/Sales (TTM)
9.28
EV/EBITDA
32.37
EV/Revenue
9.31
Dividend Yield
0.44%
Book Value
$13.32
Free Cash Flow (FY2026)
$263.22M
Free Cash Flow Yield
2.33%

Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.